Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News AstraZeneca announces positive saxagliptin results

AstraZeneca announces positive saxagliptin results

11th September 2008

AstraZeneca has presented the results of two phase III clinical studies of saxagliptin at the annual meeting for the European Association for the Study of Diabetes.

The company said the compound produced reductions across all important measures of glucose control studies when added to a sulphonylurea or thiazolidinedione in type 2 diabetes patients whose condition is inadequately controlled.

Measures of glucose control studied in the trial were glycosylated hemoglobin level (AC1), fasting plasma glucose and postprandial glucose.

Patients administered with saxagliptin with a sulphonylurea or thiazolidinedione achieved target A1C of less than seven per cent of those who did not.

Saxagliptin is a selective inhibitor with extended binding to the dipeptidyl peptidase-4 enzyme and is being jointly-developed by the company with Bristol-Myers Squibb (BMS).

Professor Anthony Barnett, of the University of Birmingham and Heart of England NHS Foundation Trust, said: “A large number of people with type 2 diabetes have difficulty managing their disease and remain uncontrolled on present therapies.”

He added that it is important to investigate new treatment options for diabetes as the number of people with the condition increases across the world.

In July 2008, AstraZeneca and BMS submitted a marketing authorisation application to the European Medicines Agency for saxagliptin under the Onglyza brand name.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.